Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $3.1 million, a 62% increase from $1.9 million in Q4 2024, driven by the U.S. launch of CGuard Prime and increased international market penetration [10] - U.S. revenue for Q4 was $866,000, representing a 74% sequential growth compared to Q3 2025 [10] - International revenue for Q4 was $2.3 million, reflecting a 17% growth compared to $1.9 million in Q4 2024 [10] - Gross profit for Q4 2025 was $1.2 million, or 37.5% of revenue, up from $469,000 or 24.1% of revenue in Q4 2024, primarily due to a favorable shift in revenue mix towards U.S. sales [11] - Net loss for Q4 2025 was $11.8 million, or $0.14 per share, compared to a net loss of $9.2 million or $0.19 per share in Q4 2024 [13] Business Line Data and Key Metrics Changes - The company has completed over 500 cases and gained approvals in prominent Integrated Delivery Networks (IDNs) in the U.S. [6] - The CGuard stent has been used in over 70,000 cases across 30 international markets, providing valuable real-world experience for the U.S. launch [6] Market Data and Key Metrics Changes - The company anticipates revenue for the full year 2026 to be in the range of $13 million to $15 million, reflecting a growth of approximately 45% to 65% over 2025 [15] - The company expects increasing sequential revenue growth in the second half of 2026, driven by anticipated FDA label expansion for CGuard Prime in TCAR procedures [16] Company Strategy and Development Direction - The company aims to achieve market leadership through a stent-first strategy, focusing on operational expansion and establishing U.S.-based production to meet growing demand [4][5] - The company is committed to continuous improvement of its products and plans to introduce enhancements to the delivery system in Q4 2026 [7][25] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the company's impact on stroke prevention and the future of endovascular care, emphasizing the importance of operational and commercial excellence [4] - The management highlighted the positive trajectory of the U.S. launch and the anticipated progress in 2026 [10][15] Other Important Information - Cash and cash equivalents and marketable securities were $54.2 million as of December 31, 2025, compared to $34.6 million at the end of the previous year [14] - The company has two remaining milestone-based tranches from a private placement, each providing gross proceeds of $17.9 million if fully exercised [14] Q&A Session Summary Question: Guidance for FY 2026 - The management expects moderate growth in OUS sales and sustained controlled launch in the U.S. for the first half, with acceleration in the second half due to anticipated TCAR indication and enhanced clinical performance [19][20] Question: Account Standpoint in the U.S. - The company has completed cases in roughly 80 centers, with over 200 centers in the pipeline for VAC and evaluation stages [23] Question: Next Generation Delivery System - The next generation delivery system is targeted for Q4 2026, with minor regulatory changes expected to go through a 30-day FDA review [25][27] Question: Timing for CGUARDIANS II Data - The first reveal of CGUARDIANS II data is expected at the Charing Cross Symposium in April [30] Question: Account Adoption and Productivity Metrics - The company aims for CGuard to become the everyday stent for physicians, with a focus on increasing account adoption and productivity [34][35]

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $3.1 million, a 62% increase from $1.9 million in Q4 2024, driven by the U.S. launch of CGuard Prime and increased international market penetration [11] - U.S. revenue for Q4 was $866,000, representing a 74% sequential growth compared to Q3 [11] - International revenue for Q4 was $2.3 million, reflecting a 17% growth compared to $1.9 million in Q4 2024 [11] - Gross profit for Q4 2025 was $1.2 million, or 37.5% of revenue, up from $469,000 or 24.1% in Q4 2024, primarily due to a favorable revenue mix towards U.S. sales [12] - Net loss for Q4 2025 was $11.8 million, or $0.14 per share, compared to a net loss of $9.2 million or $0.19 per share in Q4 2024 [14] - Cash and cash equivalents were $54.2 million as of December 31, 2025, compared to $34.6 million at the end of the previous year [14] Business Line Data and Key Metrics Changes - The CGuard Prime stent platform is central to the company's strategy, with over 500 cases completed and approvals gained in prominent Integrated Delivery Networks (IDNs) in the U.S. [5][6] - The company has established a U.S. commercial team of over 30 people, focusing on operational expansion and increasing manufacturing capacity [5] Market Data and Key Metrics Changes - The company is focusing on expanding its market presence in the U.S. and internationally, with a controlled rollout strategy to ensure sustainable growth [49] - The anticipated FDA approval for TCAR indications is expected to significantly boost market opportunities, with over 35,000 TCAR procedures performed annually [8] Company Strategy and Development Direction - The company aims to achieve market leadership through a stent-first strategy, focusing on operational excellence and customer support [4] - Plans include expanding the clinical pipeline and advancing indications for CGuard, with a focus on TCAR procedures and enhancing the delivery system [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of U.S. sales growth and the potential for continued progress in 2026, with revenue expectations between $13 million and $15 million, reflecting a growth of approximately 45%-65% over 2025 [15][16] - The company is committed to continuous improvement and exceeding customer expectations, with plans to introduce enhancements to the delivery system in Q4 2026 [26] Other Important Information - The company has two remaining milestone-based tranches from a private placement, each providing gross proceeds of $17.9 million if fully exercised [14] - The company is leveraging real-world experience from over 70,000 cases in 30 international markets to inform its U.S. launch strategy [6] Q&A Session Summary Question: Guidance for FY 2026 - The CFO provided insights on U.S. versus international sales expectations, indicating moderate growth in OUS markets and anticipated acceleration in U.S. growth in the second half of 2026 due to TCAR indication and enhanced clinical performance [18][20] Question: Account Standpoint in the U.S. - The company has completed cases in approximately 80 centers, with over 200 centers in the pipeline for VAC and evaluation stages [21][23] Question: Next Generation Delivery System - The next generation delivery system is expected to be submitted for FDA review with minor changes, aiming for a 30-day review process [25][27] Question: Timing for CGUARDIANS II Data - The first reveal of CGUARDIANS II data is expected at the Charing Cross Symposium in late April, likely presenting interim data [30] Question: Account Adoption and Productivity Metrics - The company aims for CGuard to become the everyday stent for physicians, with a focus on increasing account productivity and support [34][35]

Core Insights - InspireMD, Inc. reported strong financial results for Q4 2025, with total revenue reaching $3.1 million, a 62% increase year-over-year, and a 25% sequential increase from Q3 2025 [4][11] - The company is experiencing robust growth in the U.S. market for its CGuard Prime carotid stent system and anticipates further market expansion with upcoming approvals for TCAR procedures [3][11] - InspireMD's net loss for Q4 2025 was $11.8 million, compared to a net loss of $9.2 million in Q4 2024, indicating increased operational expenses primarily due to the expansion of the U.S. commercial team [9][13] Financial Performance - Total revenue for the full year 2025 was $9.0 million, reflecting a 28% increase from $7.0 million in 2024 [10] - U.S. revenue for 2025 was $1.4 million, while international revenue was $7.6 million, an 8% increase from the previous year [10] - Gross profit for Q4 2025 was $1.2 million, representing 37.5% of revenue, up from 24.1% in Q4 2024, driven by higher margin sales in the U.S. [6][12] Operating Expenses - Total operating expenses for Q4 2025 were $13.3 million, an increase of $3.5 million compared to Q4 2024, mainly due to increased headcount and resources for the U.S. launch of CGuard Prime [7][13] - For the full year 2025, total operating expenses were $52.3 million, up from $35.0 million in 2024, reflecting ongoing investments in commercial operations [13] Future Outlook - The company expects revenue for 2026 to be between $13 million and $15 million, indicating anticipated growth of approximately 45% to 65% over 2025 [16] - InspireMD is focused on advancing its CGuard Prime product and expanding its market presence, with plans for further catalysts in 2026 to enhance adoption [3][11]

Core Insights - The National Institutes of Health (NIH) has discontinued the low-dose rivaroxaban arm of the Phase 3 CAPTIVA stroke prevention trial due to safety concerns and lack of demonstrated benefit [1][2][3] Group 1: Trial Overview - The primary goal of the CAPTIVA trial is to assess whether rivaroxaban or ticagrelor, or both, are more effective than clopidogrel in reducing the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death [1][5] - The trial involves up to 1,683 participants across more than 100 sites over four years, as part of NIH's StrokeNet network [5] Group 2: Safety Review and Decision - An independent safety review by the Data Safety and Monitoring Board led to the decision to halt the rivaroxaban group due to increased safety events and a pre-specified futility threshold [2][3] - NIH emphasized that participant safety remains the top priority, and study sites have been instructed to stop administering the drug to participants in the discontinued arm [4] Group 3: Implications for Stroke Prevention - Rivaroxaban is an FDA-approved anticoagulant used for treating or preventing blood clots, and the discontinuation of this arm may impact future treatment strategies for stroke prevention [4][5] - The trial aims to generate additional safety and efficacy data while determining if either of the newer therapies offers an advantage over the current standard treatment [5]